Michael L. Riordan

Michael L. Riordan founded Gilead Sciences in 1987 with an initial focus on developing antifungal therapies for life-threatening infections. His defining moment was the decision to execute a desperate initial public offering in 1992 when the company was on the brink of bankruptcy, raising $86 million and providing the necessary lifeline to continue operations and pivot to antivirals. This decision established the company's long-term philosophy of taking calculated scientific risks to bring novel, life-saving therapies to patients with limited treatment options.

Michael L. Riordan is an American physician and entrepreneur who founded Gilead Sciences in 1987 and served as its CEO until 1993. He played a pivotal role in the company's early survival, navigating the severe cash crunch of the early 1990s and executing the 1992 IPO that saved the company from bankruptcy. Riordan's background as a medical doctor gave him a unique perspective on the pharmaceutical industry, driving his focus on developing therapies for life-threatening infections where patient needs were greatest. During his tenure, he oversaw the acquisition of the rights to AmBisome, which provided the company with its first commercial product and a steady stream of revenue to fund internal discovery efforts. After stepping down as CEO, Riordan remained active in the biotechnology community, serving on the boards of several major pharmaceutical companies and continuing to invest in early-stage life science startups. He is widely respected in the industry for his role in creating a global biopharmaceutical powerhouse and for his commitment to bringing novel therapies to patients with limited treatment options.